vs
Side-by-side financial comparison of AMICUS THERAPEUTICS, INC. (FOLD) and PARK NATIONAL CORP (PRK). Click either name above to swap in a different company.
AMICUS THERAPEUTICS, INC. is the larger business by last-quarter revenue ($185.2M vs $168.3M, roughly 1.1× PARK NATIONAL CORP). PARK NATIONAL CORP runs the higher net margin — 25.3% vs 0.9%, a 24.4% gap on every dollar of revenue. On growth, AMICUS THERAPEUTICS, INC. posted the faster year-over-year revenue change (23.7% vs 2.2%). PARK NATIONAL CORP produced more free cash flow last quarter ($191.9M vs $16.0M). Over the past eight quarters, AMICUS THERAPEUTICS, INC.'s revenue compounded faster (29.5% CAGR vs 4.9%).
Amicus Therapeutics, Inc. is a public American biopharmaceutical company based in Philadelphia, Pennsylvania. The company went public in 2007 under the Nasdaq trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates.
National Retail Systems, Inc. (NRS) includes Keystone Freight Corp. & National Retail Transportation, Inc. (NRT). NRS is an asset based 3PL founded in 1952. It is headquartered in Lyndhurst, New Jersey, United States.
FOLD vs PRK — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | ||
|---|---|---|
| Revenue | $185.2M | $168.3M |
| Net Profit | $1.7M | $42.6M |
| Gross Margin | 85.7% | — |
| Operating Margin | 8.6% | — |
| Net Margin | 0.9% | 25.3% |
| Revenue YoY | 23.7% | 2.2% |
| Net Profit YoY | -88.5% | 10.4% |
| EPS (diluted) | $0.00 | $2.62 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $185.2M | $168.3M | ||
| Q3 25 | $169.1M | $169.5M | ||
| Q2 25 | $154.7M | $168.7M | ||
| Q1 25 | $125.2M | $157.9M | ||
| Q4 24 | $149.7M | $164.7M | ||
| Q3 24 | $141.5M | $170.3M | ||
| Q2 24 | $126.7M | $157.7M | ||
| Q1 24 | $110.4M | $152.8M |
| Q4 25 | $1.7M | $42.6M | ||
| Q3 25 | $17.3M | $47.2M | ||
| Q2 25 | $-24.4M | $48.1M | ||
| Q1 25 | $-21.7M | $42.2M | ||
| Q4 24 | $14.7M | $38.6M | ||
| Q3 24 | $-6.7M | $38.2M | ||
| Q2 24 | $-15.7M | $39.4M | ||
| Q1 24 | $-48.4M | $35.2M |
| Q4 25 | 85.7% | — | ||
| Q3 25 | 88.5% | — | ||
| Q2 25 | 90.2% | — | ||
| Q1 25 | 90.7% | — | ||
| Q4 24 | 90.1% | — | ||
| Q3 24 | 90.6% | — | ||
| Q2 24 | 91.1% | — | ||
| Q1 24 | 87.7% | — |
| Q4 25 | 8.6% | — | ||
| Q3 25 | 20.3% | 34.3% | ||
| Q2 25 | -6.1% | 35.2% | ||
| Q1 25 | -6.3% | 32.4% | ||
| Q4 24 | 10.7% | — | ||
| Q3 24 | 15.3% | 27.4% | ||
| Q2 24 | 11.8% | 30.6% | ||
| Q1 24 | -25.1% | 27.8% |
| Q4 25 | 0.9% | 25.3% | ||
| Q3 25 | 10.2% | 27.8% | ||
| Q2 25 | -15.8% | 28.5% | ||
| Q1 25 | -17.3% | 26.7% | ||
| Q4 24 | 9.8% | 23.5% | ||
| Q3 24 | -4.8% | 22.4% | ||
| Q2 24 | -12.4% | 25.0% | ||
| Q1 24 | -43.9% | 23.0% |
| Q4 25 | $0.00 | $2.62 | ||
| Q3 25 | $0.06 | $2.92 | ||
| Q2 25 | $-0.08 | $2.97 | ||
| Q1 25 | $-0.07 | $2.60 | ||
| Q4 24 | $0.05 | $2.38 | ||
| Q3 24 | $-0.02 | $2.35 | ||
| Q2 24 | $-0.05 | $2.42 | ||
| Q1 24 | $-0.16 | $2.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | ||
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $293.5M | $233.5M |
| Total DebtLower is stronger | $392.7M | — |
| Stockholders' EquityBook value | $274.2M | $1.4B |
| Total Assets | $949.9M | $9.8B |
| Debt / EquityLower = less leverage | 1.43× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $293.5M | $233.5M | ||
| Q3 25 | $263.8M | $218.9M | ||
| Q2 25 | $231.0M | $193.1M | ||
| Q1 25 | $250.6M | $237.6M | ||
| Q4 24 | $249.9M | $160.6M | ||
| Q3 24 | $249.8M | $201.7M | ||
| Q2 24 | $260.1M | $261.5M | ||
| Q1 24 | $239.6M | $306.1M |
| Q4 25 | $392.7M | — | ||
| Q3 25 | $392.0M | — | ||
| Q2 25 | $391.3M | — | ||
| Q1 25 | $390.7M | — | ||
| Q4 24 | $390.1M | — | ||
| Q3 24 | $389.5M | — | ||
| Q2 24 | $388.9M | — | ||
| Q1 24 | $388.4M | — |
| Q4 25 | $274.2M | $1.4B | ||
| Q3 25 | $230.4M | $1.3B | ||
| Q2 25 | $204.3M | $1.3B | ||
| Q1 25 | $193.6M | $1.3B | ||
| Q4 24 | $194.0M | $1.2B | ||
| Q3 24 | $178.8M | $1.2B | ||
| Q2 24 | $132.5M | $1.2B | ||
| Q1 24 | $130.7M | $1.2B |
| Q4 25 | $949.9M | $9.8B | ||
| Q3 25 | $868.8M | $9.9B | ||
| Q2 25 | $815.3M | $9.9B | ||
| Q1 25 | $789.8M | $9.9B | ||
| Q4 24 | $785.0M | $9.8B | ||
| Q3 24 | $786.6M | $9.9B | ||
| Q2 24 | $749.5M | $9.9B | ||
| Q1 24 | $721.8M | $9.9B |
| Q4 25 | 1.43× | — | ||
| Q3 25 | 1.70× | — | ||
| Q2 25 | 1.92× | — | ||
| Q1 25 | 2.02× | — | ||
| Q4 24 | 2.01× | — | ||
| Q3 24 | 2.18× | — | ||
| Q2 24 | 2.93× | — | ||
| Q1 24 | 2.97× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | ||
|---|---|---|
| Operating Cash FlowLast quarter | $16.3M | $198.3M |
| Free Cash FlowOCF − Capex | $16.0M | $191.9M |
| FCF MarginFCF / Revenue | 8.6% | 114.1% |
| Capex IntensityCapex / Revenue | 0.2% | 3.8% |
| Cash ConversionOCF / Net Profit | 9.62× | 4.65× |
| TTM Free Cash FlowTrailing 4 quarters | $29.8M | $328.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $16.3M | $198.3M | ||
| Q3 25 | $35.7M | $52.6M | ||
| Q2 25 | $-26.5M | $49.7M | ||
| Q1 25 | $7.8M | $37.9M | ||
| Q4 24 | $-3.9M | $178.8M | ||
| Q3 24 | $-23.0M | $43.8M | ||
| Q2 24 | $22.7M | $50.9M | ||
| Q1 24 | $-29.7M | $35.0M |
| Q4 25 | $16.0M | $191.9M | ||
| Q3 25 | $35.3M | $51.1M | ||
| Q2 25 | $-28.9M | $48.4M | ||
| Q1 25 | $7.5M | $36.8M | ||
| Q4 24 | $-4.2M | $169.7M | ||
| Q3 24 | $-23.3M | $41.7M | ||
| Q2 24 | $21.6M | $49.0M | ||
| Q1 24 | $-31.5M | $31.9M |
| Q4 25 | 8.6% | 114.1% | ||
| Q3 25 | 20.9% | 30.1% | ||
| Q2 25 | -18.7% | 28.7% | ||
| Q1 25 | 6.0% | 23.3% | ||
| Q4 24 | -2.8% | 103.0% | ||
| Q3 24 | -16.5% | 24.5% | ||
| Q2 24 | 17.0% | 31.1% | ||
| Q1 24 | -28.5% | 20.8% |
| Q4 25 | 0.2% | 3.8% | ||
| Q3 25 | 0.2% | 0.9% | ||
| Q2 25 | 1.6% | 0.8% | ||
| Q1 25 | 0.2% | 0.7% | ||
| Q4 24 | 0.2% | 5.6% | ||
| Q3 24 | 0.3% | 1.2% | ||
| Q2 24 | 0.9% | 1.2% | ||
| Q1 24 | 1.6% | 2.1% |
| Q4 25 | 9.62× | 4.65× | ||
| Q3 25 | 2.06× | 1.11× | ||
| Q2 25 | — | 1.03× | ||
| Q1 25 | — | 0.90× | ||
| Q4 24 | -0.27× | 4.63× | ||
| Q3 24 | — | 1.14× | ||
| Q2 24 | — | 1.29× | ||
| Q1 24 | — | 0.99× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FOLD
| Other | $105.8M | 57% |
| Galafold | $64.8M | 35% |
| Pombiliti Opfolda | $14.6M | 8% |
PRK
Segment breakdown not available.